EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

4-O-Mono-Fructosyl Phlorizin Reduces Renal SGLT2 Immunoreactivity and Improves Metabolic Dysfunction in a High-Fat Diet/Streptozotocin-Induced Diabetic Mice

Omar Ricardo Torres-González, Javier Arrizon, Azucena Herrera-González, Sinaí Guadalupe Coronado-Gutiérrez, José Guadalupe Torres-Tolentino, Clarita Olvera-Carranza, Iván Moisés Sánchez-Hernández, Eduardo Padilla-Camberos, Angélica Sofía González-Garibay

Scientia Pharmaceutica · 18.11.2026 · 94 (4) · 115

DOI: 10.3390/scipharm94040115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientia Pharmaceutica, online erschienen am 18.11.2026. Verfasst von Omar Ricardo Torres-González und 8 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaría de Ciencia, Humanidades, Tecnología e Innovación, COECYTJAL.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, which, together with associated metabolic abnormalities, contributes to progressive damage in multiple organ systems. The development of effective and safe therapeutic alternatives remains a major research priority. Phlorizin is a dihydrochalcone that inhibits sodium-glucose cotransporter 1 and 2 (SGLT1 and SGLT2). 4-O-mono-fructosyl phlorizin (4PHF) was synthesized from phlorizin by transfructosylation with a levansucrase from Paraburkholderia phymatum (KesL) using sucrose as a donor. The in vivo antidiabetic effect of 4PHF was evaluated using a murine model of experimental diabetes (high-fat diet followed by a single streptozotocin dose). The groups were treated for 28 days as follows: the diabetic control group received distilled water, the 4PHF-treated diabetic group received 4PHF, the reference treatment group received the SGLT2 inhibitor dapagliflozin, and the non-diabetic control group received a standard diet. 4PHF exhibited a tendency to reduce blood glucose levels, increase urinary glucose excretion, and improve the lipid profile by lowering triglycerides and total cholesterol. 4PHF showed attenuation of hepatic and renal histopathological alterations. Immunohistochemistry revealed a marked decrease in SGLT2 expression and in the number of SGLT2-positive tubules in treated animals, suggesting that the treatment may modulate SGLT2 inhibition. Overall, 4PHF emerges as a promising therapeutic candidate for diabetes mellitus, as it reduces renal SGLT2 expression, improves metabolic dysfunction, and attenuates diabetes-induced hepatic and renal damage.

Förderung

  • Secretaría de Ciencia, Humanidades, Tecnología e Innovación
  • COECYTJAL

Zitieren

APA

Torres-González, O. R., Arrizon, J., Herrera-González, A., Coronado-Gutiérrez, S. G., Torres-Tolentino, J. G., Olvera-Carranza, C., Sánchez-Hernández, I. M., Padilla-Camberos, E., & González-Garibay, A. S. (2026). 4-O-Mono-Fructosyl Phlorizin Reduces Renal SGLT2 Immunoreactivity and Improves Metabolic Dysfunction in a High-Fat Diet/Streptozotocin-Induced Diabetic Mice. Scientia Pharmaceutica, 94(4), 115. https://doi.org/10.3390/scipharm94040115

Vancouver

Torres-González OR, Arrizon J, Herrera-González A, Coronado-Gutiérrez SG, Torres-Tolentino JG, Olvera-Carranza C, et al. 4-O-Mono-Fructosyl Phlorizin Reduces Renal SGLT2 Immunoreactivity and Improves Metabolic Dysfunction in a High-Fat Diet/Streptozotocin-Induced Diabetic Mice. Scientia Pharmaceutica. 2026;94(4):115. doi:10.3390/scipharm94040115

BibTeX
@article{TorresGonzlez2026,
  author = {Torres-González, Omar Ricardo and Arrizon, Javier and Herrera-González, Azucena and Coronado-Gutiérrez, Sinaí Guadalupe and Torres-Tolentino, José Guadalupe and Olvera-Carranza, Clarita and Sánchez-Hernández, Iván Moisés and Padilla-Camberos, Eduardo and González-Garibay, Angélica Sofía},
  title = {4-O-Mono-Fructosyl Phlorizin Reduces Renal SGLT2 Immunoreactivity and Improves Metabolic Dysfunction in a High-Fat Diet/Streptozotocin-Induced Diabetic Mice},
  journal = {Scientia Pharmaceutica},
  year = {2026},
  volume = {94},
  number = {4},
  pages = {115},
  doi = {10.3390/scipharm94040115}
}
Kostenlos starten →